The Wellness Center for Research and Education, Inc. - risultati della ricerca

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

trandate 200 mg compresse

aspen pharma schweiz gmbh - labetaloli hydrochloridum - compresse - labetaloli hydrochloridum 200 mg, colore.: e 110, conserv.: e 211, excipiens pro compresso haze. - alfa e beta dei recettori adrenergici - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

alpinamed arnica-gel mit spilanthes gel

alpinamed ag - spilanthis oleraceae herbae extractum ethanolicum liquidum (spilanthes oleracea l.,herba), arnicae floris extractum ethanolicum liquidum (arnica montana l., flos), arnicae radicis extractum ethanolicum liquidum (arnica montana l., radix) - gel - spilanthis oleraceae herbae extractum ethanolicum liquidum (spilanthes oleracea l.,herba) 200 mg ratio: 1:10 auszugsmittel ethanolum 62% (m/m), arnicae floris extractum ethanolicum liquidum (arnica montana l., flos) 100 mg ratio: 1:10 auszugsmittel ethanolum 63% (m/m), arnicae radicis extractum ethanolicum liquidum (arnica montana l., radix) 50 mg ratio: 1:10 auszugsmittel ethanolum 86% (m/m), ethanolum 96 per centum, aqua purificata, diisopropanolaminum, carbomerum 980, propylenglycolum 100 mg, ad gelatum 1 g, corresp. ethanolum 456 mg. - zur anwendung bei stumpfen, nicht blutenden äusserlichen verletzungen - phytoarzneimittel

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

swidro arnica-gel mit spilanthes gel

Unione Europea - italiano - EMA (European Medicines Agency)

alymsys

mabxience research sl - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - agenti antineoplastici - alymsys in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. alymsys in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. alymsys in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with alymsys in combination with capecitabine. alymsys, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer other than predominantly squamous cell histology. alymsys, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non squamous non small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations. alymsys in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. alymsys, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer. alymsys, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. alymsys, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. alymsys, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix.

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

trandate soluzione iniettabile

aspen pharma schweiz gmbh - labetaloli hydrochloridum - soluzione iniettabile - labetaloli hydrochloridum 100 mg, aqua ad iniectabile q.s. ad solutionem pro 20 ml. - alfa e beta dei recettori adrenergici - synthetika